Consensus LifeMD, Inc.

Equities

LFMD

US53216B1044

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
10.18 USD -7.96% Intraday chart for LifeMD, Inc. -11.71% +22.80%

Evolution of the average Target Price on LifeMD, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1d8ba3.5SWSVGtpCQD1h3EnFlOGiP-3U-KnFSYIRIDP7JKYeMc.qnW_ZQgtbWit1yNQJgmr5NL_EbfpX15dG-G428foDay8HeplOjluML__SQ~22a29449e2e62654ffa95501adc83511
Craig-Hallum Adjusts LifeMD's Price Target to $15 From $10, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts Price Target on LifeMD to $11 From $9, Maintains Overweight Rating MT
B. Riley Securities Lifts LifeMD's PT to $12 From $11 After 'Strong' Q4 2023 Results, Maintains Buy Rating MT
HC Wainwright Adjusts LifeMD Price Target to $12 From $10, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts LifeMD's Price Target to $9 From $8, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on LifeMD to $10 From $9, Maintains Buy Rating MT
B. Riley Raises LifeMD's Price Target to $11 From $7 After Q3 Topline Beat, Maintains Buy Rating MT
Cantor Fitzerald Adjusts LifeMD Price Target to $8 From $7, Maintains Overweight Rating MT
Cantor Fitzgerald Starts LifeMD at Overweight With $7 Price Target MT
B. Riley Raises LifeMD's PT to $7 From $3.50 on Increased Conviction for Durable Growth, Enhanced EBITDA; Keeps Buy Rating MT
HC Wainwright Initiates LifeMD With Buy Rating, $9 Price Target MT
BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating MT
BTIG Research Adjusts LifeMD Price Target to $7 From $8, Maintains Buy Rating MT
B. Riley Lowers LifeMD's Price Target to $8 from $16, Notes Slower-than-Anticipated Start in Q1 Impacted by Technology Upgrades, Integrations; Keeps Buy Rating MT
BTIG Adjusts LifeMD's Price Target to $15 From $30, Reiterates Buy Rating MT
LIFEMD : BTIG Research Adjusts LifeMD Price Target to $30 From $35, Maintains Buy Rating MT
LIFEMD : BTIG Adjusts LifeMD's Price Target to $35 From $40, Reiterates Buy Rating MT
CONVERSION LABS : B. Riley Starts Conversion Labs at Buy With $35 Price Target MT
CONVERSION LABS : BTIG Starts Conversion Labs at Buy With $15 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
10.18 USD
Average target price
12.6 USD
Spread / Average Target
+23.77%
High Price Target
15 USD
Spread / Highest target
+47.35%
Low Price Target
11 USD
Spread / Lowest Target
+8.06%

Consensus detail

Consensus revision (last 18 months)

Analysts covering LifeMD, Inc.

Craig-Hallum
Cantor Fitzgerald
B. Riley
HC Wainwright
BTIG
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings